Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome

Trial Profile

Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs TVB 2640 (Primary)
  • Indications Metabolic syndrome; Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2017 According to a 3-V Biosciences media release, data will be presented at the at the upcoming AASLD meeting at The Liver Meeting 2017.
    • 14 Feb 2017 Planned End Date changed from 1 Aug 2018 to 31 Jan 2018.
    • 14 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top